title: Dendritic cell vaccines.
abstract: Dendritic cells are antigen-presenting cells that have been shown to stimulate tumor antigen-specific T cell responses in preclinical studies. Consequently, there has been intense interest in developing dendritic cell based cancer vaccines. A variety of methods for generating dendritic cells, loading them with tumor antigens, and administering them to patients have been described. In recent years, a number of early phase clinical trials have been performed and have demonstrated the safety and feasibility of dendritic cell immunotherapies. A number of these trials have generated valuable preliminary data regarding the clinical and immunologic response to DC-based immunotherapy. The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations.
authors.affiliation: Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Mosca
authors.forename: H Kim
authors.initials: HK
authors.lastname: Lyerly
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Clay
authors.forename: Michael A
authors.initials: MA
authors.lastname: Morse
authors.forename: H Kim
authors.initials: HK
authors.lastname: Lyerly
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans
chemical_list: D019496:Cancer Vaccines